Orphan disease Treatment Institute
One of the institute's priorities is to develop diseased and patient specific stem cells for drug discovery initiatives to find treatments for orphan (rare) diseases. The institute is collaborating with Cellular Engineering Technologies to develop non-viral, cMyc-free and feeder-free induced pluripotent stem (IPS) cells. For a list of orphan diseases, go to the Orphan Disease List page.
What are IPS cells?
IPS cells are pluripotent stem cells that have the same properties as embryonic stem cells, but do not have the same ethical controversy because embryos are not used. The below figure describes the process. Adult cells derived from a patient are genetically reprogrammed by the introduction of multiple genetic elements. Transformed IPS cells then can convert into all of the same 200 specialized cells as embryonic stem cells. The advantage of IPS cells is that it avoids using embryos and the stem cells are specific to a patient.
Utility of IPS cells:
These cells can then be used as test models to screen drugs with research tools to find treatments for patients (See below figure).
Despite the increased financial expenditures in medical research, the number of FDA-approved drugs over time has been decreasing. The Institute’s goal is to serve as a catalyst, with a novel model that incorporates the private medical practice sector as an equal partner to increase the drug discovery output and productivity for academia, government and industry.
The Institute is recruiting doctors to participate in our research activities to find treatments and cures for patients with rare orphan diseases. A rare orphan disease is defined as a disease with less than 200, 000 suffering from a specific ailment. The Institute and CET have created a research program to accelerate drug development by creating stem cell models from patients with rare diseases, which can be utilize to screen drugs that potentially can be investigated in clinical trials. These stem cell will be utilized to screen drugs that potentially could be used as therapies for patients. The Institute is actively recruiting patients with the following disorders to develop stem cell lines for screening drugs: (1) Lysosomal Storage Diseases; (2) Genetic Diseases; (3) Neurological Diseases with Strong Family History –e.g. Alzheimer and Parkinson Disease, ADHD, dyslexia, Autism and ALS.
You might also like
HIV & AIDS: The Ultimate Guide To Living With HIV And AIDS: (kindle ebooks, kindle short reads, aids orphans, aids history, aids epidemic, aids africa, ... and memoirs, 20th century american history)